RT Journal Article
SR Electronic
T1 Understanding pediatric long COVID using a tree-based scan statistic approach: An EHR-based cohort study from the RECOVER Program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.08.22283158
DO 10.1101/2022.12.08.22283158
A1 Lorman, Vitaly
A1 Razzaghi, Hanieh
A1 Rao, Suchitra
A1 Jhaveri, Ravi
A1 Case, Abigail
A1 Mejias, Asuncion
A1 Pajor, Nathan M.
A1 Patel, Payal
A1 Thacker, Deepika
A1 Bose-Brill, Seuli
A1 Block, Jason
A1 Hanley, Patrick C.
A1 Prahalad, Priya
A1 Chen, Yong
A1 Forrest, Christopher B.
A1 Bailey, L. Charles
A1 Lee, Grace M.
YR 2022
UL http://medrxiv.org/content/early/2022/12/11/2022.12.08.22283158.abstract
AB Objectives Post-acute sequalae of SARS-CoV-2 infection (PASC) is not well defined in pediatrics given its heterogeneity of presentation and severity in this population. The aim of this study is to use novel methods that rely on data mining approaches rather than clinical experience to detect signals associated with PASC.Materials and Methods We used a propensity-matched cohort design comparing children identified using the new PASC ICD10CM diagnosis code (U09.9) (N=1250) to children with (N=6250) and without (N=6250) SARS-CoV-2 infection. We used a tree-based scan statistic to identify potential condition clusters co-occurring more frequently in cases than controls.Results We found significant enrichment among children with PASC in cardiac, respiratory, neurologic, psychological, endocrine, gastrointestinal, and musculoskeletal systems, the most significant related to circulatory and respiratory such as dyspnea, difficulty breathing, and fatigue and malaise.Discussion Our study addresses methodological limitations of prior studies that rely on pre-specified clusters of potential PASC-associated diagnoses driven by clinician experience. Future studies are needed to identify patterns of diagnoses and their associations to derive clinical phenotypes.Conclusion We identified multiple conditions and body systems associated with pediatric PASC. Because we rely on a data-driven approach, several new or under-reported conditions and symptoms were detected that warrant further investigation.Competing Interest StatementDr. Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. Dr. Mejias reports funding from Janssen and Merck for research support; Janssen, Merck and Sanofi-Pasteur for Advisory Board participation, and Sanofi-Pasteru and AstraZeneca for CME lectures. Dr. Patel reports funding from the National Institute of Health and Bayer Pharmaceuticals Dr Brill received support from Novartis and Regeneron Pharmaceuticals within in the last year Dr. Chen receives consulting support from GSK Dr Bailey has received grants from Patient-Centered Outcomes Research Institute All other authors have nothing to disclose.Funding StatementThis research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Children's Hospital of Philadelphia's institutional review board designated this study as not human subjects research and the need for consent was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.